Moteur de recherche d’entreprises européennes
Financement de l’UE (14,6 M €) : Infrastructure européenne de recherche et de développement de vaccins Hor01/05/2017 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Infrastructure européenne de recherche et de développement de vaccins
TRAN???C2 is the follow-up project to its successful predecessor project TRAN???C, the European Network of Vaccine Research and Development funded under FP7. The TRAN???C2 consortium comprises a comprehensive collection of leading European institutions that propose to further advance with the previous initiative towards the establishment of a fully operational and sustainable European vaccine R&D infrastructure. TRAN???C2 will support innovation for both prophylactic and therapeutic vaccine development based on a disease-overarching and one-health approach, thereby optimising the knowledge and expertise gained during the development of both human and animal vaccines. This will be achieved by bridging the translational gap in biomedical research, and by supporting cooperation between public vaccine R&D institutions of excellence, related initiatives and networks in Europe, and industrial partners. TRAN???C2 will complement and integrate with existing European research infrastructures in both the public and private sectors. TRAN???C2 will function as leverage and innovation catalyst between all stakeholders involved in vaccine R&D in Europe and -by providing integrated and overarching vaccine R&D services- will contribute to the development of effective products to address European and global health challenges, to controlling the burden and spread of infectious diseases, and reinforce the economic assets represented by vaccine developers in Europe. The impact of TRAN???C2 will be maximised by two external advisory bodies. An independent Scientific & Ethics Advisory Committee will provide recommendations surrounding scientific-technical and ethical issues, whereas the coordination of TRAN???C2 with other related initiatives and the further promotion of the long-term stability of a European vaccine R&D infrastructure will be supported by a Board of Stakeholders comprising representatives of policy and decision makers, industry associations and European infrastructures.
| Academisch Ziekenhuis Leiden | 555 000 € |
| 191 903 € | |
| Commissariat a L Energie Atomique et aux Energies Alternatives | 1 513 270 € |
| 660 499 € | |
| EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH | 288 000 € |
| EUROPEAN VACCINE INITIATIVE e. V. | 1 309 122 € |
| 261 831 € | |
| Ecrin European Clinical Research Infrastructure Network | 226 750 € |
| FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG e. V. | 518 904 € |
| 108 993 € | |
| HELMHOLTZ-ZENTRUM für INFEKTIONSFORSCHUNG GmbH | 486 691 € |
| 916 708 € | |
| Institut National de Recherche Pour l'Agriculture, l'Alimentation et l'Environnement | 202 284 € |
| Institut de Recerca i Tecnologia Agroalimentaries | 729 867 € |
| Instruct Academic Services Ltd. | 29 260 € |
| 138 599 € | |
| Istituto Superiore DI Sanita | 0,00 € |
| 130 833 € | |
| Masarykova Univerzita | 0,00 € |
| 196 377 € | |
| 75 320 € | |
| Statens Serum Institut | 645 028 € |
| Stichting Biomedical Primate Research Center | 2 576 814 € |
| Stichting Wageningen Research | 471 015 € |
| The Chancellor, Masters and Scholars of the University of Oxford | 640 595 € |
| 0,00 € | |
| UNIVERSITE DE LAUSANNE | 0,00 € |
| Universita Degli Studi DI Siena | 738 243 € |
| Universiteit Leiden | 235 450 € |
| Vaccine Formulation Institute Ltd. | 709 379 € |
https://cordis.europa.eu/project/id/730964
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
Les visualisations de "Academisch Ziekenhuis Leiden - Financement de l’UE (14,6 M €) : Infrastructure européenne de recherche et de développement de vaccins"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
